Participants 41 135 6
cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17
Participants 437 474 3
cetuximab-treated patients with ACRC.
Participants 773 888 7
five hundred and seventy-two patients were included; 41% were â‰¥ 65 years and 25% had comorbidities at randomizati
